AstraZeneca's oncology sales jump 18% in second-quarter 2025, fueled by key drugs and new launches like Truqap and Datroway.

Continued progress across pipeline programs with focus on pancreatic cancer Mid-year report of Ampligen® (rintatolimod) in ...

With its domination of the indication- and brand-specific analyses, it should come as no surprise that AstraZeneca led the ...

In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

AstraZeneca PLC thrives with $54B revenue and 14 blockbusters in 2024, fueled by oncology and rare disease growth. Click for ...

AstraZeneca (AZ) has announced that Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) has been recommended by ...

The supplemental Biologics License Application for the gastric/GEJ cancer indication is supported by data from the double-blind, placebo-controlled MATTERHORN trial.

The US Food and Drug Administration (FDA) has granted priority review to durvalumab for the treatment of patients with resectable, stage II-IVA gastric or gastroesophageal junction (GEJ) cancer.

AstraZeneca has received a positive recommendation from NICE for the use of Imfinzi (durvalumab) with Imjudo (tremelimumab) in adults with advanced or unresectable hepatocellular carcinoma (HCC). The ...

AstraZeneca ’s AZN second-quarter 2025 core earnings of $1.09 per American depositary share (ADS) came in line with the Zacks ...